1 / 83

Defining the Role of EGFR Monoclonal Antibody Therapy in Metastatic Colorectal Cancer

Defining the Role of EGFR Monoclonal Antibody Therapy in Metastatic Colorectal Cancer. Author: Dr. Phil Bedard Date Posted: December 12, 2007. Objectives. Review the rationale for targeting EGFR in metastatic colorectal cancer therapy

mitchell
Télécharger la présentation

Defining the Role of EGFR Monoclonal Antibody Therapy in Metastatic Colorectal Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Defining the Role of EGFR Monoclonal Antibody Therapy in Metastatic Colorectal Cancer Author: Dr. Phil Bedard Date Posted: December 12, 2007

  2. Objectives • Review the rationale for targeting EGFR in metastatic colorectal cancer therapy • Outline the differences between the monoclonal antibodies against EGFR • Understand the common toxicities associated with EGFR monoclonal antibodies • Summarize the evidence supporting the use of EGFR monoclonal antibody therapy in the first-, second-, and third-line treatment of metastatic CRC • Discuss possible methods of selection of patients most likely to benefit from EGFR monoclonal antibody blockade with metastatic CRC

  3. Epidermal Growth Factor Receptor (EGFR) • Member of the epidermal growth factor receptor tyrosine kinase family • Ligand binding to extracellular domain leads to activation of intracellular signaling cascade, including Akt and MAPK • Results in proliferation, angiogenesis, increased cell motility, and resistance to chemotherapy

  4. EGFR in Colorectal Cancer • Expressed in 60-80% CRC • Risk factor for poor prognosis • Monoclonal antibodies (mAb) demonstrate activity as single agents and in combination with chemotherapy in CRC • To date, there is no proof that small molecular tyrosine kinase inhibitors (TKIs) are of benefit • CRC lacks EGFR mutations that have been asssociated with response to TKIs in other disease sites Townsley CA Br J Cancer 2006 Rothernberg ML JCO 2005

  5. Monoclonal AntibodiesAgainst EGFR • For treatment of metastatic colorectal cancer: • Cetuximab approved by Health Canada and FDA • Panitumumab approved by FDA

  6. Comparison: Cetuximab vs Panitumumab

  7. First-line Therapy:Cetuximab + Chemotherapy

  8. CRYSTAL Trial 10 Endpoint= PFS RANDOMI ZE FOLFIRI + Cetuximab N=648 N=1198 EGFR expression via IHC FOLFIRI N=650 * Cetuximab 400 mg/m2 IV week 1 then 250 mg/m2 IV weekly 1:1 Van Custem E Proc ASCO 2007

  9. Toxicity

  10. Efficacy p=0.0038 HR = 0.85 (0.73-0.99); p=0.048

  11. PFS by Skin Reaction:FOLFIRI + Cetuximab * No Grade 4 Reaction Reported

  12. OPUS: Phase II RANDOMI ZE FOLFOX + Cetuximab N=170 N=338 EGFR+ Metasatic CRC FOLFOX N=168 * Cetuximab 400 mg/m2 IV week 1 then 250 mg/m2 IV weekly 1:1

  13. Toxicity

  14. Efficacy * No Survival Data Reported

  15. Response Rate by Skin Rash

  16. SWOG 80203 10 Endpoint= OS FOLFOX + Cetuximab RE GISTER RANDOMI ZE FOLFOX Inv choice FOLFOX alone FOLFIRI + Cetuximab FOLFIRI Inv choice FOLFIRI alone N=258 Metastatic Colorectal CA No EGFR expression required 1:1 Venook A Proc ASCO 2006

  17. SWOG 80203 • Planned sample size N=2200 • Trial stopped early January 2005 because of poor accrual • Publication of Hurwitz data with IFL + Bevacizumab (NEJM 2004) • Data reported with median F/U 16 months

  18. Efficacy

  19. Toxicity

  20. Efficacy: Cetuximabversus Chemotherapy Alone

  21. Medical Research Council: COIN Trial (Ongoing) 10 Endpoint= OS RANDOMI ZE FOLFOX/CapeOX until progression/intolerance N=2421 (Target) No EGFR testing FOLFOX/CapeOX + Cetuximab until progression/intolerance FOLFOX/CapeOXx12 weeks “Stop & Go” Strategy 1:1:1

  22. First-line Therapy:Panitumumab + Chemotherapy

  23. PRIME Trial: Ongoing 10 Endpoint= PFS RANDOMI ZE Panitumumab + FOLFOX N=900 (Target Accrual) Metastatic Colorectal CA No EGFR testing FOLFOX alone Expected Completion: March 2010 1:1

  24. First-line Therapy:Ceutximab + Chemotherapy + anti-VEGF

  25. CALGB/SWOG 80405: Ongoing 10 Endpoint= OS RANDOMI ZE FOLFOX or FOLFIRI + Bevacizumab + Cetuximab N=2300 (Target) Metastatic Colorectal CA No EGFR testing FOLFOX or FOLFIRI + Cetuximab FOLFOX or FOLFIRI + Bevacizumab 1:1:1

  26. Dutch Colorectal Cancer Group CAIRO-2: Ongoing N=750 (Target Accrual) Metastatic Colorectal CA No EGFR testing 10 Endpoint= PFS & Toxicity RANDOMI ZE CapeOX + Bevacizumab + Ceutximab CapeOX + Bevacizumab Expected Completion: December 2007 1:1

  27. Preliminary Toxicity Data

  28. First-line Therapy:Panitumumab + Chemotherapy + anti-VEGF

  29. Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) Panitumumab + Oxali-CT + Bevacizumab RE GISTER RANDOMI ZE Oxali-based CT (ie FOLFOX) Inv choice Oxali-CT + Bevacizumab Panitumumab + Iri-CT + Bevacizumab Iri-based CT (ie FOLFIRI) Inv choice Iri-CT + Bevacizumab 1:1 Hecht JR GI World Congress 2007

  30. PACCE • Trial stopped early after interim analysis suggested excess toxicity and inferior efficacy in treatment arm

  31. Toxicity

  32. Efficacy HR = 1.29 (1.05-1.58) HR = 1.44 (1.10-1.88)

  33. Summary: First Line • CRYSTAL trial suggests that Cetuximab can be safely combined with FOLFIRI in first line setting, with very modest lengthening of PFS of uncertain clinical importance • PACCE trial demonstrates significant added toxicity with combination of chemotherapy, anti-VEGF therapy and Panitimumab • Similar toxicity not reported with CAIRO-2 trial using chemotherapy, anti-VEGF therapy and Cetuximab • Data presently do not support routine use of EGFR mAb therapy in combination with chemotherapy +/- anti-VEGF therapy in first-line setting

  34. Second-line Therapy:Cetuximab + Chemotherapy

  35. Erbitux Plus Irinotecan in Colorectal Cancer (EPIC) RANDOMI ZE 10 Endpoint= PFS Cetuximab + Irinotecan N=648 Prior Oxaliplatin Chemotherapy EGFR+ (IHC) Irinotecan alone N=650 Cetuximab 400mg/m2 week 1; then 250mg/m2 weekly Irinotecan 350mg/m2 q3weekly 1:1 Sobrero AF AACR 2007

  36. Toxicity

  37. Efficacy HR = 0.69 (0.62-0.78) HR = 0.98 (0.85-1.11)

  38. Post-Study Therapy

  39. Survival by Skin Reaction: Cetuximab + Irinotecan

  40. MRC: EXPLORE RANDOMI ZE 10 Endpoint= OS Cetuximab + FOLFOX N=52 Prior Irinotecan Chemotherapy EGFR+ (IHC) Metastatic CRC N=102 FOLFOX N=50 Cetuximab 400mg/m2 week 1; then 250mg/m2 weekly 1:1 Polikoff Proc ASCO 2005

  41. EXPLORE • Planned sample size N=1100 • Trial stopped early December 2004 because of poor accrual • Widespread adoption of FOLFOX in first-line setting

  42. Efficacy p=0.48

  43. Second-line Therapy:Panitumumab + Chemotherapy

  44. Panitumumab, Irinotecan & Cyclosporin in COLOrectal Cancer Therapy (PICCOLO): Ongoing 10 Endpoint= PFS RANDOMI ZE Irinotecan + Panitumumab N=1269 (Target) Prior 5-FU +/- Oxali +/- Bev No EGFR testing Irinotecan + Cyclosporin Irinotecan alone 1:1:1

  45. Second-line Therapy:Cetuximab + Chemotherapy + anti-VEGF

  46. SWOG S0600/ECOG/NCCTG/NCIC: Ongoing 10 Endpoint= OS RANDOMI ZE Irinotecan/FOLFIRI + Cetuximab + Bevacizumab N=1250 (Target) Prior Oxali-based CT Prior Bev allowed No EGFR testing No Prior anti-EGFR therapy Irinotecan/FOLFIRI + Cetuximab Irinotecan/FOLFIRI + Bevacizumab 1:1:1

  47. Summary - Second Line • EPIC trial shows that addition of Cetuximab to FOLFIRI produces statistically significant improvement in response rate and PFS • PFS improvement of questionable clinical significance with no overall survival benefit and added toxicity • lack of OS benefit due to cross over to cetuximab setting on progression in standard arm • S0600 will address whether addition of Cetuximab + anti-VEGF therapy to Irinotecan-based treatment can improve OS after progression on oxaliplatin-based chemotherapy • At present, data do not support routine use of anti-EGFR mAb therapy in 2nd line setting

  48. Third-line Therapy:Cetuximab Monotherapy

  49. NCIC CO.17 REGISTER RANDOMI ZE 10 Endpoint= OS Cetuximab* + BSC EGFR testing by IHC Best Supportive Care alone * Cetuximab 400 mg/m2 IV week 1 then 250 mg/m2 IV weekly 1:1 N=572 Prior 5FU, Iri, and Oxali-CT EGFR expression required • Stratification: • Centre • ECOG PS (0 or 1 vs. 2) Jonker DJ NEJM 2007

  50. Patient Characteristics

More Related